

## Rhythm Biosciences enters ColoSTAT® services agreement with 4Cyte Pathology

### Highlights

- ✓ Rhythm has entered into a non-exclusive ColoSTAT® Product Distribution Service Agreement with 4Cyte Pathology, one of Australia's largest independent pathology providers.
- ✓ 4Cyte will integrate ColoSTAT® into its clinical ordering system across its network of over 1,000 patient collection centres in New South Wales, Victoria, and Queensland.
- ✓ 4Cyte will support patient sample collection through its phlebotomy network, with serum samples transported to the Rhythm ISO 15189-accredited laboratory in Parkville, Victoria for analysis. Results will be delivered back to the referring healthcare practitioner via 4Cyte's established reporting systems.
- ✓ Rhythm will perform testing and invoice patients directly for ColoSTAT® tests. There are no minimum volume commitments or upfront payments under the Agreement.
- ✓ The partnership provides access to an established clinical ordering and collection network to support increased distribution of ColoSTAT®, complementing the Company's existing ColoSTAT® Access Program and direct-to-practitioner channels.

---

**Melbourne, Australia, 17th February 2026:** Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX:RHY), a predictive cancer diagnostics technology company is pleased to announce that it has entered into a ColoSTAT® Distribution Service Agreement ('Agreement') with 4Cyte Pathology Pty Ltd ('4Cyte'), one of Australia's largest independent, privately owned pathology providers.

### Background and Strategic Rationale

Rhythm's ColoSTAT® test is a blood-based diagnostic for the detection of colorectal cancer ('CRC') that measures five specific protein biomarkers to indicate the likelihood of CRC. The test is designed as an alternative screening pathway for individuals with symptoms of bowel cancer who are unable or unwilling to complete faecal-based screening methods such as the faecal immunochemical test (FIT).

**Rhythm Biosciences Ltd**  
ACN 619 459 335  
ASX: RHY

**Australian Registered Address**  
Bio21 Molecular Science & Biotechnology Institute  
30 Flemington Road  
Parkville VIC 3010 Australia

**Directors**  
Gavin Fox-Smith Non-Executive Chairman  
Sue MacLeman Non-Executive Director  
David Atkins CO & Managing Director

[www.rhythmbio.com](http://www.rhythmbio.com)

T +61 3 8256 2880  
E [info@rhythmbio.com](mailto:info@rhythmbio.com)

The Company has been progressing commercialisation through the ColoSTAT® Access Program, which provides access to the test via direct referral pathways.

The distribution agreement aims to support the expansion of the Company's commercial reach by leveraging an established, scaled pathology network to integrate ColoSTAT® into routine clinical workflows.

### About 4Cyte

4Cyte is an independent, privately owned Australian pathology provider founded in 2017. It operates over 1,000 patient collection centres across New South Wales, Australian Capital Territory, Victoria, and Queensland, supported by NATA-accredited laboratories.

4Cyte services a broad network of general practitioners, specialists, and medical centres across the Australian eastern seaboard.

### Material Terms of the Distribution Agreement

The key terms of the Distribution Agreement are summarised below:

Term	Description
<b>Parties</b>	Rhythm Biosciences Ltd (ASX: RHY) and 4Cyte Pathology Pty Ltd.
<b>Subject</b>	Non-exclusive distribution of the ColoSTAT® clinical testing service through 4Cyte's pathology network in Australia.
<b>Initial Term</b>	Three (3) years from commencement, with an option for a two (2) year extension by mutual agreement.
<b>Exclusivity</b>	Non-exclusive. Rhythm retains the right to appoint additional distributors or provide ColoSTAT® services directly in all Australian jurisdictions.
<b>Scope of Services</b>	4Cyte will: (i) integrate ColoSTAT® into its clinical ordering system; (ii) facilitate ordering by referring healthcare practitioners; (iii) support patient sample collection via its phlebotomy and collection centre network; (iv) coordinate sample transport to the Rhythm

	laboratory in Parkville, VIC; and (v) deliver results to the referring healthcare practitioner.
<b>Testing &amp; Analysis</b>	All ColoSTAT® sample analysis will be performed at Rhythm's ISO 15189:2022-accredited laboratory in Parkville, Victoria.
<b>Revenue Model</b>	Revenue is generated on a per-test basis. Rhythm will perform testing and invoice patients directly. There is no upfront payments, minimum commitments, or material capital expenditure required by either party.
<b>IP &amp; Data</b>	All intellectual property rights in ColoSTAT® remain with Rhythm. Patient data handling will comply with applicable Australian privacy legislation.
<b>Termination</b>	Standard termination provisions, including for material breach and convenience with appropriate notice periods.

### Commercial Significance

The Agreement provides Rhythm with access to an established clinical ordering and specimen collection network across multiple Australian jurisdictions.

By integrating ColoSTAT® into 4Cyte's existing workflows, operational barriers for healthcare practitioners seeking to order the test for their patients should be reduced.

Some additional key commercial benefits of the partnership include:

1. Immediate access to over 1,000 patient collection centres across three states, providing substantial geographic coverage of the Australian east coast population. Leverage of 4Cyte's existing phlebotomy and courier logistics for sample collection and transport, reducing the need for Rhythm to invest in duplicative collection infrastructure.
2. Complementary promotional capability through 4Cyte's clinical engagement with general practitioners and specialists across its network.

3. A capital efficient, variable cost structure with no upfront capital commitment, aligning the Company's cost base with actual testing volumes during the early commercialisation phase.

### **Impact on Financial Position**

The Agreement does not involve any upfront payments, material capital commitments, or minimum volume guarantees from either party.

Revenue under the agreement will be generated on a per-test basis as ColoSTAT® tests are ordered by healthcare practitioners and performed at the Rhythm laboratory. Testing volumes are uncertain and there is no guarantee of revenue generation under the Agreement as testing volumes will depend on healthcare practitioner adoption rates, which are not yet established. The Company will provide updates on testing volumes and commercial progress as part of its regular reporting.

The Agreement is funded from existing operational budgets and resources. No additional capital is required to support the implementation of the partnership.

### **Commentary**

Dr David Atkins, CEO & Managing Director of Rhythm Biosciences, commented:

*"We have gained valuable experience working with the 4Cyte team with Genetype and are delighted to be expanding our relationship. This partnership enables healthcare practitioners to order ColoSTAT® through the same systems they already use for routine pathology, removing a key barrier to adoption. With colorectal cancer screening participation in Australia remaining below 50%, there is a clear and urgent need for alternative screening pathways. This partnership positions ColoSTAT® to be accessed through established pathology workflows and potentially address that unmet need at scale."*

### **Next Steps**

Rhythm and 4Cyte will now work to complete technical integration of ColoSTAT® into 4Cyte's clinical ordering systems and establish operational workflows for sample collection, transport, and results delivery.

Timing of commercial rollout will depend on completion of integration and operational readiness. The Company will provide further updates as additional milestones in the partnership are achieved.

- ENDS -

**This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.**

**For further information contact us via [investors@rhythmbio.com](mailto:investors@rhythmbio.com).**

#### **About Rhythm Biosciences**

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and X.

#### **About ColoSTAT®**

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

#### **About geneType™**

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit [www.genetype.com](http://www.genetype.com).